Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. (Q38004628)

26 August 2017

title

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. (English)

1 reference

26 August 2017

1 reference

1 reference

Paolo Antonio Ascierto

series ordinal

2

object named as

Paolo A Ascierto

1 reference

26 August 2017

1

Ester Simeone

1 reference

26 August 2017

language of work or name

1 reference

23 April 2012

1 reference

Journal of Immunotoxicology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

241-247

1 reference

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Checkpoint blockade in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F1547691X.2012.678021

10.3109/1547691X.2012.678021

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference